PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of neurologyNeurologyAmerican Academy of Neurology
 
Neurology. Aug 14, 2012; 79(7): 633–641.
PMCID: PMC3414665
Serum ceramides increase the risk of Alzheimer disease
The Women's Health and Aging Study II
Michelle M. Mielke, PhD,corresponding author
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • Dr. Mielke was funded by the following NIH grants: U01 AG037526, role: PI, Date: 08/15/2010-06/30/2015; R21 NS06027-01, role: PI, Date: 07/15/07-06/30/09; R21 AG028754, role: PI, Date: 09/01/07-08/31/09’ R01 AG21136, role: Investigator, Date: 9/01/02-8/31/08
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • Dr. Mielke also received research support from the George and Cynthia Mitchell Foundation. Role: co-PI, Date: 07/01/2007-06/30/2010.
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Veera Vankata Ratnam Bandaru, PhD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Norman J. Haughey, PhD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • R01 AA0017408 (Haughey, PI). 9/27/07 – 8/31/12 NIAAA Interaction of Alcohol with HIV-Protein Using in vitro and in vivo models of HIV-dementia, we propose to determine the mechanisms of how alcohol dysregulates neuronal function in acute, chronic and withdrawal conditions. R01 MH077542 (Haughey, PI) 9/17/07 – 5/31/12 NIMH Dysfunctions of Sphingolipid and Sterol Metabolism in HIV-Dementia In this application we will test the central hypothesize that the HIV-1 proteins gp120 and Tat alter the sphingolipid composition of neuronal membranes and cluster post-translationally modified NMDA receptors in lipid rafts. R21AG034849-01 (Haughey, PI)4/1/10 – 3/31/12 NIA Perturbation of Amyloid Processing in HAND The goals of this application are to determine the mechanisms by which the HIV coat protein gp120 promotes aberrant amyloid processing and amyloid-beta deposition. 2 P30 MH075673-06 (McArthur)7/1/11 – 6/30/16 NIMH Center for novel therapeutics for HIV-associated cognitive disorders Role: Director of Surrogate Markers Core, Co-Director Therapeutics Core. U01AG037526-01 (Mielke, PI) 7/1/10 – 6/30/151 Mayo Clinic/NIA Longitudinal Study of Lipids and APOE in the Development of AD and AD Pathology The overall aim of the proposed study is to examine, in the 50-year Baltimore Longitudinal Study of Aging, whether plasma lipids measured in mid-life (sphingolipids, gangliosides, fatty acids, cholesterol and cholesterol esters) modify the association between APOE and cognitive decline, clinical onset of mild cognitive impairment or AD, and neuroimaging measures of brain atrophy and brain pathology. Role: Co-I.
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Jin Xia, MS,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Linda P. Fried, MD, MPH,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NIH Grant R37AG19905 in the role of Principal Investigator for years covering 2001-present.
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Sevil Yasar, MD, PhD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • Charles River Laboratories
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • Sanofi
Research Support, Government Entities:
  • NIH/NIDA; DA-10-013 - Subcontract from UCI, PI, 2011-2012 NIH/NIA; T32AG000247 - Clinical practicum director,2006 - 2011
Research Support, Academic Entities:
  • JHU Pepper Center
Research Support, Foundations and Societies:
  • R. Bosch Foundation, Germany J. A. Hartford Foundation
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Marilyn Albert, PhD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • Consultant to: Genentech, Eli Lilly, Eisai, Agenebio and Dana Foundation,
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • GE - Site for GE 067-005 study
Research Support, Government Entities:
  • Grants from NIH: NIH/NIA, U01-AG033655 (PI) 2009 - present NIH/NIA, P50 AG005146 (PI) 2009 - present
Research Support, Academic Entities:
  • Massachusetts General Hospital, Harvard Medical School
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • Stock options from Agenebio (2011- )
Legal Proceedings:
  • NONE
Vijay Varma, MPH,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Greg Harris, BS,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Eric B. Schneider, PhD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • Method for treating acute CNS trauma
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • Bergeim, LLC., Development of treatment for acute CNS injury
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • 1. Agency for Healthcare Research and Quality, K08 HS17952, Co-investigator, 2011-2012 2. National Institute of General Medical Sciences, K23GM093112-01, Co-investigator
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • 1. American Gastroenterological Association Foundation, Co-investigator, 2009 - 2010
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Peter V. Rabins, MD, MPH,
Scientific Advisory Boards:
  • Data safety monitoring board for the VA Health System
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • International Journal of Geriatric Psychiatry-not compensated International Psychogeriatrics-not compensated
Patents:
  • NONE
Publishing Royalties:
  • 36-Hour Day, Johns Hopkins Press 2011
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NIA, NIMH
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • Legal testimony for Janssen Pharmaceutica
Karen Bandeen-Roche, PhD,
Scientific Advisory Boards:
  • Scientific review for NIH (related to frailty in older adults)
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • A few reimbursements for lectures at universities and the NIH (related to statistical methods)
Editorial Boards:
  • Journal of Gerontology, Medical Sciences, statistical consultant, 2006-present
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NIH/NIA P30AG021334, Co-PI, 07/01/08 – 06/30/13 NCRR, UL1RR025005, Core Leader, 09/17/07 – 05/31/12 NIH/NIMH, P30MH086043, Core Leader, 07/01/09 – 02/28/14 AHRQ, TO6-HHSA29020050034I, Co-investigator,07/20/10 – 07/19/13 NIH/NIDB, R01DA022366, Co-investigator, 03/15/08 – 12/31/11 NIH/NIA,P50AG005146, Core Leader, 04/01/10 – 03/31/15 NIH/NIA, R01AG019604, Co-investigator, 05/01/08 – 04/30/12 NIH/NIA, R01AG027236, Co-investigator, 09/01/06 – 08/31/11
Research Support, Academic Entities:
  • Columbia University, Subcontract
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • Pfizer, many years, held by my mother
Legal Proceedings:
  • NONE
Constantine G. Lyketsos, MD, MHS,
Scientific Advisory Boards:
  • Commercial: Elan, Lilly, Avanir, Forest, Takeda, Pfizer, NFLPA. Non-profit DSMB: Indiana University.
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NFLPA, Alzheimer’s Association, AAGP.
Editorial Boards:
  • No compensation: International Review of Psychiatry, International Psychogeriatrics, Psychosomatics, ADRD.
Patents:
  • NONE
Publishing Royalties:
  • Oxford Press
Employment, Commercial Entity:
  • Johns Hopkins University.
Consultancies:
  • Elan, Lilly, Takeda, Pfizer, NFL Benefits.
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • Forest.
Research Support, Government Entities:
  • NIH, NIMH, NIA, Alzheimer’s Association.
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
and Michelle C. Carlson, PhD
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
From the Division of Epidemiology (M.M.M.), Department of Health Sciences Research, College of Medicine, Mayo Clinic, Rochester, MN; Department of Psychiatry, Division of Geriatric Psychiatry and Neuropsychiatry (N.J.H., P.V.R., C.G.L.), Department of Neurology (V.V.R.B., N.J.H., M.A.), Center on Aging and Health (J.X., S.Y., V.V., G.H., M.C.C.), Department of Medicine, Division of Geriatric Medicine & Gerontology (S.Y.), and Department of Surgical Trials and Outcomes Research (E.B.S.), Johns Hopkins University School of Medicine, Baltimore, MD; Mailman School of Public Health (L.P.F.), Columbia University, New York, NY; and Departments of Mental Health (V.V., M.C.C.) and Biostatistics (K.B.-R.), Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD.
corresponding authorCorresponding author.
Correspondence & reprint requests to Dr. Mielke: mielke.michelle/at/mayo.edu
Study funding: Supported in part by grants from the National Institute on Aging R37 AG19905, R01 AG19825–01, R03 AG032427–01A1, P50 AG005146–27, and U01 AG037526–01, the National Institute of Neurological Disorders and Stroke grant R21 NS060271, and the Johns Hopkins Older Americans Independence Center (1 P30 AG021334–01).
Received November 10, 2011; Accepted February 23, 2012.
Objectives:
Previous studies have shown that high serum ceramides are associated with memory impairment and hippocampal volume loss, but have not examined dementia as an outcome. The aim of this study was to examine whether serum ceramides and sphingomyelins (SM) were associated with an increased risk of all-cause dementia and Alzheimer disease (AD).
Methods:
Participants included 99 women without dementia aged 70–79, with baseline serum SM and ceramides, enrolled in a longitudinal population-based study and followed for up to 6 visits over 9 years. Baseline lipids, in tertiles, were examined in relation to all-cause dementia and AD using discrete time Cox proportional survival analysis. Lipids were analyzed using electrospray ionization tandem mass spectrometry.
Results:
Twenty-seven (27.3%) of the 99 women developed incident dementia. Of these, 18 (66.7%) were diagnosed with probable AD. Higher baseline serum ceramides, but not SM, were associated with an increased risk of AD; these relationships were stronger than with all-cause dementia. Compared to the lowest tertile, the middle and highest tertiles of ceramide d18:1–C16:0 were associated with a 10-fold (95% confidence interval [CI] 1.2–85.1) and 7.6-fold increased risk of AD (95% CI 0.9–62.1), respectively. The highest tertiles of ceramide d18:1–C24:0 (hazard ratio [HR] = 5.1, 95% CI 1.1–23.6) and lactosylceramide (HR = 9.8, 95% CI 1.2–80.1) were also associated with risk of AD. Total and high-density lipoprotein cholesterol and triglycerides were not associated with dementia or AD.
Conclusions:
Results from this preliminary study suggest that particular species of serum ceramides are associated with incident AD and warrant continued examination in larger studies.
Lipidomic, metabolomic, and targeted approaches have identified pathways and products of sphingolipid metabolism that are altered early in the course of Alzheimer disease (AD).15 Ceramides facilitate the regulation of β-site APP cleaving enzyme 1 (BACE-1) and γ-secretase activity and amyloid precursor protein (APP) processing and trafficking. Evidence also suggests that glycosphingolipids bind amyloid-β (Aβ) at the cell surface and form domains that facilitate the oligomerization and fibril formation of Aβ.610 In addition to these roles, ceramide is a potent regulator of cell survival. Upon activation, ceramide-associated protein kinases and phosphatases evoke proapoptotic signaling pathways,1115 leading to neurodegeneration.
Despite the abundant laboratory and animal findings linking sphingolipids and AD pathology, little research has extended these findings to examine the role of sphingolipids in AD pathogenesis among humans. The few postmortem, and 1 CSF, studies suggest ceramide and SM levels, and gene expression patterns of enzymes participating in the sphingolipid pathway, vary by AD severity.13,16,17 We have shown that blood ceramide levels vary by cognitive status, and that elevations of ceramides in subjects with amnestic mild cognitive impairment (MCI) predict cognitive decline and hippocampal volume loss.18 In a separate study we also found that high blood ceramides in cognitively normal women predicted memory impairment.19 However, not all individuals with memory impairment progress to dementia or AD.20 Therefore, we were unable to determine whether increased blood ceramides predicted dementia or AD, or were a general indicator of cognitive impairment. The goal of the present pilot study was to determine whether serum ceramides predicted all-cause dementia or were specifically associated with AD.
Study sample.
The Women's Health and Aging Study II (WHAS II) is a prospective study of physical functioning among the two-thirds least disabled 70- to 79-year-old community-dwelling women in Baltimore, MD. The sampling and recruitment of this cohort have been previously described.21,22 Using the Health Care Financing Administration's Medicare eligibility lists for 12 zip code areas in Eastern Baltimore City and County, age-stratified (70–74, 75–79) random samples were drawn by Westat, Inc. in 1994–1995. Trained interviewers screened 1,630 women and determined eligibility according to whether women 1) were aged 70 to 79 years; 2) had sufficient hearing and English proficiency to be interviewed; 3) could be contacted by telephone; 4) had a Mini-Mental State Examination score ≥24; and 5) reported no, or limited, difficulty in only 1 of the following 4 domains: mobility and exercise tolerance, upper extremity function, high-functioning tasks, and basic self-care. Of 880 women screened eligible, 436 (49.5%) agreed to participate in the baseline examination at the Johns Hopkins Hospital and to prospective follow-up. Those agreeing to participate were more educated and had more diseases than those who refused, but did not differ on other characteristics.21,22 For the present study, 223 women had adequate serum baseline samples remaining in storage. Due to the limited blood reserved, we randomly selected 100 participants' serum samples for the lipid assays. Follow-ups were conducted 1.5, 3, 6, 7.5, and 9 years after baseline. Each examination consisted of a comprehensive medical history, medication inventory, physical and neurologic examination, neuropsychological battery, and blood draw.
Standard protocol approvals, registrations, and patient consent.
The study was approved by The Johns Hopkins University institutional review board. Written informed consent was obtained for all participants who were examined as part of the study.
Dementia adjudication.
The pool of WHAS II participants for dementia adjudication was chosen from the larger WHAS II cohort (n = 436) based on 3 criteria: Mini-Mental State Examination (MMSE) score <24, history of stroke (either self-report or diagnosed), or a decrease in MMSE score of >2 points between 2 consecutive rounds (with the exception of the extended 3-year window between visits 3 and 4). A total of 239 WHAS II participants met these criteria. These participants were adjudicated through a consensus conference in collaboration with the Johns Hopkins AD Research Center and included neuropsychologists, geriatric psychiatrists, geriatricians, epidemiologists, and faculty and staff involved in WHAS II. During each adjudication session, all available information on each participant was reviewed, including up to 9 years of medical and neurologic history, cognitive test performance, and proxy reports of daily functioning and cognitive problems. Consensus conferences diagnosed mild cognitive impairment, dementia, and dementia type using the National Alzheimer's Coordinating Center approach, which is used in all AD Research Centers. Dementia was initially diagnosed according to DSM-IV criteria23 at each WHAS II visit. The age at onset was assigned as the age when each participant unambiguously met DSM-IV criteria for dementia. Possible and probable AD were diagnosed according to National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association criteria.24 In order to account for the differences in the adjudication process over time, 20% (approximately 50 participants) were adjudicated twice in a masked fashion. There was 85% agreement (κ = 0.68) between adjudication sessions.
Cholesterol and triglyceride assays.
Nonfasting blood was drawn at baseline and serum was frozen at −80°C until processing. Total and high-density lipoprotein (HDL) cholesterol and triglycerides were determined using standard enzymatic techniques at Quest Diagnostics.
Sphingolipid assays.
A crude lipid extract was performed using previously published methods.25 In brief, methanol containing 30 mM ammonium acetate (3 volumes/weight) was added to each serum sample containing internal standards ceramide d18:1–C12:0 and sphingomyelin d18:1–C12:0 (1.3 μg/mL of extraction solvent) and the mixture was vortexed. Chloroform (4 volumes/weight) was added and the mixture was vortexed and centrifuged at 1,000 g for 10 minutes. The chloroform layer was removed and dried in a vacuum oven. Dried samples were resuspended in 100% methanol (200 μL) just prior to analysis by high-pressure liquid chromatography coupled tandem mass spectrometry.
Samples were injected using a Harvard Apparatus pump at the rate of 15 μL/min into a Sciex API3000 electrospray ionization triple stage quadruple tandem mass spectrometer (ESI-MS/MS; Thornhill, Ontario, Canada) operated in the positive mode. The ESI-MS/MS scanned from 300 to 1,000 atomic mass units (amu) per second at a step of 0.1 amu. Each lipid species was initially identified by a Q1 mass scan, then by precursor ion scanning or neutral loss scanning of a purified standard. Samples were injected into the ESI-MS/MS for 3 minutes, where the mass counts accumulate and the sum of the total counts under each peak were used to quantitate each analyte. SM and ceramide reference standards were purchased from Avanti Polar Lipids (Alabaster, AL).
Covariates.
To examine whether sphingolipids levels varied by demographic and health-related characteristics, we first assessed the association between these variables and tertiles of SM and ceramide species using analysis of variance for continuous variables and Fisher exact test for dichotomous variables. Potential covariates included baseline age, race, education, smoking status, and minutes of exercise per week; medical conditions and symptoms such as systolic and diastolic blood pressure, diabetes, myocardial infarction, stroke, angina, peripheral artery disease, and depression; statins and other medications; and serum total and HDL cholesterol, triglycerides, blood glucose, creatinine, and albumin levels. Of these variables, blood glucose was consistently higher and body mass index (BMI) lower in the highest tertile of all sphingolipids. Multivariable analyses controlled for baseline blood glucose levels, BMI, and age.
Statistical analysis.
SM species were highly correlated (p < 0.0001) after Bonferroni correction. We therefore summed all SM species to create a single (total) SM variable. Individual ceramides species were less correlated so these species were examined separately. SM and ceramides were analyzed in tertiles because they were highly skewed to the right. t Tests and Fisher exact tests were used to compare the 100 randomly selected women with available baseline samples and the 123 women with available samples who were not selected. Differences between the 100 women with assayed lipids and the rest of the population (n = 336), regardless of sample availability, were also examined.
Among the 100 participants with assayed serum sphingolipids, 1 person with prevalent dementia at baseline was excluded from the analysis, leaving a total of 99 individuals. Additionally, 9 participants developed non-AD dementia, and were therefore excluded from the analysis examining SM and ceramides as a risk factor for AD. Due to the time interval feature of WHAS II data, the discrete time Cox proportional hazards model with a complementary log-log link was used to assess the effect of baseline lipid levels on the risk of developing all-cause dementia or AD.26 Exponentiated coefficients from the model can be interpreted as hazard ratios (HRs). Participants were included in longitudinal analyses if they received a baseline evaluation and at least 1 additional follow-up. For each outcome, participants contributed information up to the examination at which they first developed dementia, died, or were lost to follow-up and therefore censored. Multivariate models controlled for age, blood glucose, and BMI. The a priori p value was p < 0.05. Analyses were conducted using SAS version 9.2 (SAS Institute Inc., Cary, NC).
The 100 participants with SM and ceramide assays were slightly younger (74.0 vs 74.7; p = 0.036) and had lower baseline systolic blood pressure (148.6 vs 153.5; p = 0.047) compared to the rest of the sample (n = 336). No other health or demographic characteristics differed between the 2 groups, including baseline cognitive test scores. Among the 223 women with available baseline serum samples, there were no differences between the 100 women randomly selected for the study and the 123 women with available stored bloods but who were not randomly selected. Of the 99 women in the all-cause dementia analyses, 27 (27.3%) developed incident dementia over the 9-year follow-up (this percentage is similar to the 24.8% that developed dementia in the full cohort); 18 of the 27 (66.7%) dementia cases were diagnosed with probable AD. There were no baseline demographic or health-related differences between those who did and those who did not develop all-cause dementia or AD (table 1). The average participant follow-up time in our study sample was 8.2 years (SD = 2.4) with a mean of 5.3 study visits (SD = 1.2) for individuals without dementia and 6 years (SD = 2.5) and 4.1 study visits (SD = 1.2) for those with incident dementia. Total risk time evaluated was 755.1 risk years for all-cause dementia vs no dementia analyses and 710.4 risk years for AD vs no dementia analyses.
Table 1
Table 1
Baseline characteristics of participants without dementia, with any dementia type, and with Alzheimer disease
The number of events in each lipid tertile and corresponding incidence rates for all-cause dementia and AD are shown in tables 2 and and3,3, respectively. Using multivariable discrete time survival analysis to examine serum lipids as predictors of incident dementia (table 2), the highest tertile of lactosylceramide was associated with an increased risk of all-cause dementia (HR = 4.3; 95% confidence interval [CI] 1.1–16.1). Additionally, compared to the lowest tertile, the middle tertile of ceramide d18:1–C16:0 (HR = 3.8; 95% CI 1.2–12.5) was associated with an increased risk of all-cause dementia, while the effect of the highest tertile was attenuated and not significantly different from the lowest tertile (p = 0.137). Figure 1 displays the Kaplan-Meier plots for incident dementia by baseline tertiles of ceramide d18:1–C16:0 and lactosylceramide.
Table 2
Table 2
Baseline serum lipids, in tertiles, predict incident dementiaa
Table 3
Table 3
Baseline serum lipids, in tertiles, predict incident Alzheimer disease
Figure 1
Figure 1
Kaplan-Meier plot for incident dementia
Higher baseline serum ceramides were also associated with an increased risk of AD, and the relationships were stronger than that seen when examining all-cause dementia as the outcome (table 3). Notably, there was only one case of AD in the lowest tertile of ceramides d18:1–C16:0, d18:1–C22:0, and lactosylceramide. There was also a threshold effect for most ceramides such that both the second and third tertiles exhibited an increased risk of AD, although the results were not always significant at the p < 0.05 level. For example, compared to the lowest tertile, the second tertile of ceramide d18:1–C16:0 was associated with a 10-fold increased risk of AD (95% CI 1.2–85.1) and the highest tertile was associated with a 7.6-fold increased risk (95% CI 0.9–62.1). The highest tertiles of ceramide d18:1–C24:0 (HR = 5.1; 95% CI 1.1–23.6) and lactosylceramide (HR = 9.8; 95% CI 1.2–80.1) were also associated with an increased risk of AD. Figure 2 displays the Kaplan-Meier plots for incident AD by baseline tertiles of lactosylceramides and ceramides d18:0–C16:0, d18:1–C22:0, and d18:1–C24:0.
Figure 2
Figure 2
Kaplan-Meier plot for incident Alzheimer disease (AD)
To determine the specificity of the associations, we also examined other baseline serum lipid levels, including total and HDL cholesterol and triglycerides, but did not find associations between these lipids and incident all-cause dementia or AD (tables 2 and and3).3). In additional analyses, baseline SM and ceramide levels were not associated with loss to follow-up (data not shown).
In this population-based sample of older women, high serum ceramide levels (especially ceramides d18:1–C16:0, d18:1–C24:0, and lactosylceramide) were associated with an increased risk of all-cause dementia independent of age, blood glucose, and BMI. Importantly, the relationship between these lipids and AD was much stronger than for all-cause dementia, with an HR of about 10 and an apparent threshold effect. Only 1 person in the lowest tertile of serum ceramides d18:1–C16:0 and d18:1–C22:0 and lactosylceramide developed AD dementia. These findings suggest that high levels of serum ceramides increase the risk of developing AD.
Accumulating evidence suggests that ceramide metabolism may be perturbed early in the pathogenesis of AD.2,16,17,27 While the exact mechanisms by which this happens is an active area of research, a number of studies have identified pathogenic links between ceramides and amyloid-β (Aβ). First, exposure of cultured neurons to Aβ1–42 directly increases ceramide levels by activating neutral sphingomyelinase2830; inhibiting this ceramide production protects neurons from Aβ1–42-induced cell death.16 Second, Aβ1–42 indirectly increases ceramide production through an oxidative stress-mediated mechanism.16,31 Ceramides then increase inflammatory and reactive oxygen species, further enhancing the pathology in a self-sustaining way. Finally, increased levels of ceramides accelerate the formation of pathogenic forms of amyloid by increasing β- and γ-cleavage of APP.3235 These results suggest that a disruption of ceramide metabolism may be an early and critical event involved in Aβ production and the neuronal dysfunction associated with AD.4
We have previously reported that high blood ceramide levels varied by AD severity and were predictive of cognitive decline and hippocampal volume loss among clinically adjudicated patients with amnestic MCI.18 The present study supports these findings by showing that high ceramide levels, particularly ceramides d18:1–C16:0, d18:1–C24:0, and lactosylceramide, are most strongly associated with an increased risk of AD dementia. Notably in previous shotgun and targeted studies of blood and brain ceramides,1,16,18,19 the ceramide d18:1–C24:0 has consistently been altered.
There was a threshold effect for both incident dementia and AD such that the HR of the highest tertile was similar or lower than the middle tertile. Thus, it is possible that low ceramide levels reduce the risk of dementia/AD, rather than that high levels are detrimental. Future studies with larger sample sizes are needed to better determine this threshold effect. Additionally, normal ceramide and SM levels have not been adequately established. Thus, we used tertiles because our data were in cycles per second, and not in easily quantifiable clinical units. Ongoing research is examining normal levels in the population and will be essential to define abnormal values, whether high or low, for risk of dementia and AD.
The exact mechanism by which blood ceramides could contribute to AD is currently unknown, but both direct and indirect mechanisms have been suggested.4 Among HIV-infected participants we have found a significant correlation between plasma and CSF ceramides,36 suggesting that there is a relation between blood measures of ceramides and brain levels. As HIV disruptions of the blood–brain barrier could be driving this association, additional research examining the blood–CSF relationship of sphingolipids in AD is ongoing. Indirect mechanisms may also contribute. Both ceramides and SM increase the risk of cardiovascular disease and insulin resistance,3739 both of which are associated with an increased risk of AD. In the present study, we examined several vascular factors as mediators of the ceramide–AD relationship and found no attenuation of the relationship between serum ceramides and AD, but additional examination is needed in a larger study.
Several limitations warrant consideration. First, this sample was composed of women and may not be generalizable to men. However, there are currently no results from other studies to suggest the relationship should be different among men. Second, serum lipids were only assayed at baseline, leaving open the possibility that change in these biomarkers may be a better indicator of progression. Third, lipids were nonfasting and the effect of fasting on SM and ceramides is not clear. Correcting for fasting status by controlling for blood glucose had little effect on point estimates. Finally, while there was a high retention rate in this cohort (55.7% of the 436 participants completed all 6 examinations), over 9 years 90 participants died21 and some individuals were lost to follow-up (n = 103) and may have developed dementia, leading to a potential underdetection of cases and a conservative estimate of the lipid–dementia associations. The findings from this small study of women warrant replication in a larger population-based sample to verify the results.
Despite these limitations, there are several strengths. WHAS II is a longitudinal, population-based study that allowed us to examine the specificity of associations between blood SM and ceramides and incident dementia. Women had up to 6 examinations, and 9 years of follow-up. Second, dementia diagnoses were conducted via consensus conference and in collaboration with the Johns Hopkins AD Research Center. Finally, despite the small sample size, effect sizes were quite large and specific to ceramides.
In this preliminary study, high serum ceramide levels were associated with an increased risk of AD and warrant replication in a larger study. Additional research is also needed in larger studies to determine whether there are mediating vascular factors or whether the timing of the measurement (midlife vs late life) is important. The present results, combined with the current literature, call for additional examination into ceramide metabolites as potential new targets for the prevention or treatment of AD.
GLOSSARY
amyloid-β
ADAlzheimer disease
amuatomic mass units
APPamyloid precursor protein
BACE-1β-site APP cleaving enzyme 1
BMIbody mass index
CIconfidence interval
DSM-IVDiagnostic and Statistical Manual of Mental Disorders, 4th edition
ESI-MS/MSelectrospray ionization tandem mass spectrometry
HDLhigh-density lipoprotein
HRhazard ratio
MCImild cognitive impairment
MMSEMini-Mental State Examination
SMsphingomyelin
WHAS IIWomen's Health and Aging Study II.

AUTHOR CONTRIBUTIONS
Dr. Mielke: drafting/revising the manuscript for content, including medical writing for content, study concept or design, analysis and interpretation of data, obtaining funding. Dr. Bandaru: drafting/revising the manuscript for content, analysis or interpretation of data. Dr. Haughey: drafting/revising the manuscript for content, including medical writing for content, study concept or design, analysis or interpretation of data. Ms. Xia: drafting/revising the manuscript for content, statistical analysis, Interpretation of the data. Dr. Fried: drafting/revising the manuscript for content, including medical writing for content, study concept or design. Dr. Yasar: drafting/revising the manuscript for content, including medical writing for content, study concept or design, interpretation of data. Dr. Albert: drafting/revising the manuscript for content, including medical writing for content, interpretation of data. Mr. Varma: study concept or design, drafting/revising the manuscript for content, including medical writing for content. Mr. Harris: study concept or design, drafting/revising the manuscript for content, including medical writing for content. Dr. Schneider: study concept or design, drafting/revising the manuscript for content, including medical writing for content. Dr. Rabins: drafting/revising the manuscript for content, including medical writing for content, interpretation of data. Dr. Bandeen-Roche: analysis and interpretation of data, drafting/revising the manuscript for content, including medical writing for content. Dr. Lyketsos: drafting/revising the manuscript for content, including medical writing for content, interpretation of the data. Dr. Carlson: drafting/revising the manuscript for content, including medical writing for content, study concept or design, interpretation of the data, obtaining funding.
DISCLOSURE
M. Mielke, V.V.R. Bandaru, N. Haughey, J. Xia, L. Fried, S. Yasar, M. Albert, V. Varma, G. Harris, E. Schneider, P. Rabins, and K. Bandeen-Roche report no disclosures. C. Lyketsos has received grant support (research or CME) from the following organizations: NIMH, NIA, Associated Jewish Federation of Baltimore, Weinberg Foundation, Forest, GlaxoSmithKline, Eisai, Pfizer, Astra-Zeneca, Lilly, Ortho-McNeil, Bristol-Myers, and Novartis. Dr. Lyketsos has served as a consultant/advisor for Astra-Zeneca, GlaxoSmithKline, Eisai, Novartis, Forest, Supernus, Adlyfe, Takeda, Wyeth, Lundbeck, Merz, Lilly, and Genentech. Dr. Lyketsos has received honorarium or travel support from Pfizer, Forest, GlaxoSmithKline, and Health Monitor. M. Carlson reports no disclosures. Go to Neurology.org for full disclosures.
1. Han X, Rozen S, Boyle SH, et al. Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One 2011; 6: e21643 . [PMC free article] [PubMed]
2. He X, Huang Y, Li B, Gong CX, Schuchman EH. Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiol Aging 2010; 31: 398– 408. [PMC free article] [PubMed]
3. Katsel P, Li C, Haroutunian V. Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease? Neurochem Res 2007; 32: 845– 856. [PubMed]
4. Mielke MM, Lyketsos CG. Alterations of the sphingolipid pathway in Alzheimer's disease: new biomarkers and treatment targets? Neuromolecular Med 2010; 12: 331– 340. [PMC free article] [PubMed]
5. Haughey NJ, Bandaru VV, Bae M, Mattson MP. Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis. Biochim Biophys Acta 2010; 1801: 878– 886. [PMC free article] [PubMed]
6. Chi EY, Ege C, Winans A, et al. Lipid membrane templates the ordering and induces the fibrillogenesis of Alzheimer's disease amyloid-beta peptide. Proteins 2008; 72: 1– 24. [PubMed]
7. Chi EY, Frey SL, Lee KY. Ganglioside G(M1)-mediated amyloid-beta fibrillogenesis and membrane disruption. Biochemistry 2007; 46: 1913– 1924. [PubMed]
8. Kim SI, Yi JS, Ko YG. Amyloid beta oligomerization is induced by brain lipid rafts. J Cell Biochem 2006; 99: 878– 889. [PubMed]
9. Kakio A, Nishimoto S, Yanagisawa K, Kozutsumi Y, Matsuzaki K. Interactions of amyloid beta-protein with various gangliosides in raft-like membranes: importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid. Biochemistry 2002; 41: 7385– 7390. [PubMed]
10. Ikeda K, Yamaguchi T, Fukunaga S, Hoshino M, Matsuzaki K. Mechanism of amyloid beta-protein aggregation mediated by GM1 ganglioside clusters. Biochemistry 2011; 50: 6433– 6440. [PubMed]
11. Bourbon NA, Yun J, Kester M. Ceramide directly activates protein kinase C zeta to regulate a stress-activated protein kinase signaling complex. J Biol Chem 2000; 275: 35617– 35623. [PubMed]
12. Oh HL, Seok JY, Kwon CH, Kang SK, Kim YK. Role of MAPK in ceramide-induced cell death in primary cultured astrocytes from mouse embryonic brain. Neurotoxicology 2006; 27: 31– 38. [PubMed]
13. Detre C, Kiss E, Varga Z, et al. Death or survival: membrane ceramide controls the fate and activation of antigen-specific T-cells depending on signal strength and duration. Cell Signal 2006; 18: 294– 306. [PubMed]
14. Stoica BA, Movsesyan VA, Lea PM, 4th, Faden AI. Ceramide-induced neuronal apoptosis is associated with dephosphorylation of Akt, BAD, FKHR, GSK-3beta, and induction of the mitochondrial-dependent intrinsic caspase pathway. Mol Cell Neurosci 2003; 22: 365– 382. [PubMed]
15. Shen YH, Godlewski J, Zhu J, et al. Cross-talk between JNK/SAPK and ERK/MAPK pathways: sustained activation of JNK blocks ERK activation by mitogenic factors. J Biol Chem 2003; 278: 26715– 26721. [PubMed]
16. Cutler RG, Kelly J, Storie K, et al. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci USA 2004; 101: 2070– 2075. [PubMed]
17. Satoi H, Tomimoto H, Ohtani R, et al. Astroglial expression of ceramide in Alzheimer's disease brains: a role during neuronal apoptosis. Neuroscience 2005; 130: 657– 666. [PubMed]
18. Mielke MM, Haughey NJ, Ratnam Bandaru VV, et al. Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss. Alzheimers Dement 2010; 6: 378– 385. [PMC free article] [PubMed]
19. Mielke MM, Bandaru VV, Haughey NJ, Rabins PV, Lyketsos CG, Carlson MC. Serum sphingomyelins and ceramides are early predictors of memory impairment. Neurobiol Aging 2010; 31: 17– 24. [PMC free article] [PubMed]
20. Manly JJ, Tang MX, Schupf N, Stern Y, Vonsattel JP, Mayeux R. Frequency and course of mild cognitive impairment in a multiethnic community. Ann Neurol 2008; 63: 494– 506. [PMC free article] [PubMed]
21. Carlson MC, Fried LP, Xue QL, Bandeen-Roche K, Zeger SL, Brandt J. Association between executive attention and physical functional performance in community-dwelling older women. J Gerontol B Psychol Sci Soc Sci 1999; 54: S262– 270. [PubMed]
22. Fried LP, Bandeen-Roche K, Chaves PH, Johnson BA. Preclinical mobility disability predicts incident mobility disability in older women. J Gerontol A Biol Sci Med Sci 2000; 55: M43– 52. [PubMed]
23. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 4th ed Washington, DC: American Psychiatric Association; 2000. ..
24. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939– 944. [PubMed]
25. Bandaru VV, Troncoso J, Wheeler D, et al. ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer's but not normal brain. Neurobiol Aging 2009; 30: 591– 599. [PMC free article] [PubMed]
26. Cox DR. Regression models and life-tables (with discussion). J Royal Stat Soc B 1972; 34: 187– 202 .
27. Han X, Holtzman DM, McKeel DW, Jr, Kelley J, Morris JC. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J Neurochem 2002; 82: 809– 818. [PubMed]
28. Grimm MO, Grimm HS, Patzold AJ, et al. Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat Cell Biol 2005; 7: 1118– 1123. [PubMed]
29. Jana A, Pahan K. Fibrillar amyloid-beta peptides kill human primary neurons via NADPH oxidase-mediated activation of neutral sphingomyelinase: Implications for Alzheimer's disease. J Biol Chem 2004; 279: 51451– 51459. [PMC free article] [PubMed]
30. Lee JT, Xu J, Lee JM, et al. Amyloid-beta peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. J Cell Biol 2004; 164: 123– 131. [PMC free article] [PubMed]
31. Mattson MP, Cutler RG, Jo DG. Alzheimer peptides perturb lipid-regulating enzymes. Nat Cell Biol 2005; 7: 1045– 1047. [PubMed]
32. Cordy JM, Hussain I, Dingwall C, Hooper NM, Turner AJ. Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc Natl Acad Sci USA 2003; 100: 11735– 11740. [PubMed]
33. Kalvodova L, Kahya N, Schwille P, et al. Lipids as modulators of proteolytic activity of BACE: involvement of cho-lesterol, glycosphingolipids, and anionic phospholipids in vitro. J Biol Chem 2005; 280: 36815– 36823. [PubMed]
34. Vetrivel KS, Cheng H, Lin W, et al. Association of gamma-secretase with lipid rafts in post-Golgi and endosome membranes. J Biol Chem 2004; 279: 44945– 44954. [PMC free article] [PubMed]
35. Puglielli L, Ellis BC, Saunders AJ, Kovacs DM. Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. J Biol Chem 2003; 278: 19777– 19783. [PubMed]
36. Bandaru VV, Mielke MM, Chu M, et al. CSF sphingolipids are biomarkers for neurocognitive status in HIV-infected patients. In: 10th International Symposium on Neurovirology, Milan, Italy, October 12–16, 2010. ..
37. Ichi I, Nakahara K, Miyashita Y, et al. Association of ceramides in human plasma with risk factors of atherosclerosis. Lipids 2006; 41: 859– 863. [PubMed]
38. Nelson JC, Jiang XC, Tabas I, Tall A, Shea S. Plasma sphingomyelin and subclinical atherosclerosis: findings from the multi-ethnic study of atherosclerosis. Am J Epidemiol 2006; 163: 903– 912. [PubMed]
39. Summers SA. Sphingolipids and insulin resistance: the five Ws. Curr Opin Lipidol 2010; 21: 128– 135. [PubMed]
Articles from Neurology are provided here courtesy of
American Academy of Neurology